FrancophonIA/ELRC3.0 huggingface dataset:
English: A similar trend was observed in a sub-group analysis of treatment-experienced patients with baseline HIV-1 RNA < 75 copies/ml from a retrospective cohort study (data collected over 20 months, see Table 5).
Croatian: Sličan trend uočen je u retrospektivnom kohortnom istraživanju, u analizi podskupine prethodno liječenih bolesnika s početnom razinom HIV-1 RNA < 75 kopija/ml (podaci prikupljani tijekom 20 mjeseci, vidjeti Tablicu 5).
English: This effect is due to induction of CYP3A4 or P-gp by efavirenz and may result in loss of therapeutic effect of elbasvir/grazoprevir (see section 4.5).
Croatian: Do ovog učinka dolazi zbog indukcije CYP3A4 ili P-glikoproteina (P-gp) efavirenzom i može dovesti do gubitka terapijskog učinka elbasvira/grazoprevira (vidjeti dio 4.5).
English: Nervous system symptoms associated with efavirenz usually begin during the first one or two days of therapy and generally resolve after the first two to four weeks.
Croatian: Simptomi od strane živčanog sustava povezani s efavirenzom obično počinju tijekom prvog, ili prva dva dana terapije i uglavnom nestaju nakon prva dva do četiri tjedna.
English: When used in combination with efavirenz and two NRTIs, 533/133 mg lopinavir/ritonavir (soft capsules) twice daily yielded similar lopinavir plasma concentrations as compared to lopinavir/ritonavir (soft capsules) 400/100 mg twice daily without efavirenz (historical data).
Croatian: U slučaju uzimanja dva puta dnevno u kombinaciji s efavirenzom i dva NRTI lijeka, 533/133 mg lopinavira/ritonavira (meke kapsule) dovodi do sličnih koncentracija lopinavira u plazmi u usporedbi s lopinavirom/ritonavirom (meke kapsule) u dozi 400/100 mg dva puta dnevno, bez efavirenza (podaci iz prošlosti).
English: When using Atripla with low-dose ritonavir, the possibility of an increase in the incidence of efavirenz-associated adverse events should be considered, due to possible pharmacodynamic interaction.
Croatian: Ako se Atripla daje s niskim dozama ritonavira, nužno je uzeti u obzir veću mogućnost pojave štetnih događaja povezanih s efavirenzom zbog moguće farmakodinamičke interakcije.
English: Maraviroc:
Croatian: maravirok:
English: Co-administration with elbasvir/grazoprevir due to the expected significant decreases in plasma concentrations of elbasvir and grazoprevir.
Croatian: Istodobna primjena s elbasvirom/grazoprevirom zbog očekivanih značajnih smanjenja koncentracija elbasvira i grazoprevira u plazmi.
English: Hepatitis C antivirals Elbasvir/Grazoprevir + Efavirenz
Croatian: Antivirusni lijekovi protiv hepatitisa C elbasvir/grazoprevir + efavirenz elbasvir:
English: GMR=geometric least-squares mean ratio, CI=confidence interval
Croatian: GMR=omjer geometrijskih srednjih vrijednosti najmanjih kvadrata, IP=interval pouzdanosti
English: Voriconazole: Co-administration of standard doses of efavirenz and voriconazole is contraindicated.
Croatian: Vorikonazol: Istodobna primjena standardnih doza efavirenza i vorikonazola je kontraindicirana.
English: Renal impairment: As Atripla may cause renal damage, monitoring of renal function is recommended (see sections 4.4 and 4.8 Summary of the safety profile).
Croatian: Oštećenje funkcije bubrega: Atripla može prouzročiti oštećenje bubrega, pa se preporučuje praćenje funkcije bubrega (vidjeti dijelove 4.4 i 4.8 Sažetak profila sigurnosti primjene).
English: Vigabatrin/Emtricitabine Gabapentin/Emtricitabine
Croatian: vigabatrin/emtricitabine gabapentin/emtricitabin
English: For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines.
Croatian: Za praćenje lipida i glukoze u krvi date su preporuke u utvrđenim smjernicama za liječenje HIV-a.
English: In combination studies evaluating the in vitro antiviral activity of efavirenz and emtricitabine together, efavirenz and tenofovir together, and emtricitabine and tenofovir together, additive to synergistic antiviral effects were observed.
Croatian: U kombiniranim istraživanjima u kojima je ispitivana in vitro zajednička antivirusna aktivnost efavirenza i emtricitabina, efavirenza i tenofovira te emtricitabina i tenofovira, zapaženi su aditivni do sinergistički antivirusni učinci.
English: Resistance to emtricitabine or tenofovir has been seen in vitro and in some HIV-1 infected patients due to the development of an M184V or M184I substitution in RT with emtricitabine or a K65R substitution in RT with tenofovir.
Croatian: Rezistencija na emtricitabin ili tenofovir opažena je in vitro te u nekih bolesnika koji su inficirani virusom HIV-1 uslijed razvoja supstitucije RT na položaju M184V ili M184I kod emtricitabina ili supstitucije RT na položaju K65R kod tenofovira.
English: In patients with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 µg•h/ml (19%) of emtricitabine, and over 48 hours to 42,857 ng•h/ml (29%) of tenofovir.
Croatian: U bolesnika sa završnim stadijem bubrežne bolesti (ESRD, end-stage renal disease) koji trebaju hemodijalizu, izloženost lijeku između dijaliza znatno se povećala tijekom 72 sata na 53 (19%) µg•h/ml emtricitabina, a tijekom 48 sati na 42 857 (29%) ng•h/ml tenofovira.
English: Bone problems (sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, Possible side effects).
Croatian: Tegobe s kostima (koje ponekad dovode do prijeloma) mogu se također pojaviti zbog oštećenja stanica bubrežnih kanalića (pogledajte dio 4, Moguće nuspojave).
English: Anencephaly and unilateral anophthalmia with secondary enlargement of the tongue were observed in one foetus, microophthalmia was observed in another foetus and cleft palate was observed in a third foetus.
Croatian: Na jednom zametku uočena je anencefalija i unilateralna anoftalmija sa sekundarnim povećanjem jezika, na drugom zametku uočena je mikrooftalmija, a na trećem rascijepljeno nepce.
English: 3 See section 4.8 Description of selected adverse reactions for more details.
Croatian: 3 Dodatne podatke potražite u odjeljku 4.8 Opis odabranih nuspojava.
English: Both emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA polymerases and there was no evidence of toxicity to mitochondria in vitro and in vivo.
Croatian: I emtricitabin trifosfat i tenofovir difosfat slabi su inhibitori DNK polimeraza sisavaca, a toksičnost po mitohondrije nije dokazana in vitro niti in vivo.
English: Efavirenz+ emtricitabine+ tenofovir disoproxil (N=244)
Croatian: efavirenz+emtricitabin+ tenofovirdizoproksil (N=244)
English: Atripla can be reinitiated in patients interrupting therapy because of rash.
Croatian: Može se ponovo započeti s davanjem Atriple bolesnicima u kojih je terapija prekinuta zbog osipa.
English: Efavirenz, emtricitabine and tenofovir have been shown to be excreted in human milk.
Croatian: Pokazalo se da se efavirenz, emtricitabin i tenofovir izlučuju u majčino mlijeko.
English: QTc prolongation has been observed with the use of efavirenz (see sections 4.5 and 5.1).
Croatian: Opaženo je produljenje Qc intervala kod primjene efavirenza (vidjeti dijelove 4.5 i 5.1).
English: Patients had never experienced virological failure on a previous antiretroviral therapy, had no known HIV-1 mutations that confer resistance to any of the three components within Atripla, and had been virologically suppressed for at least three months at baseline.
Croatian: U bolesnika nikada nije došlo do virološkog neuspjeha u prethodnim antiretrovirusnim liječenjima, nisu imali nikakve poznate mutacije virusa HIV-1 odgovorne za rezistenciju na bilo koju od tri komponente od kojih se sastoji Atripla i u početku su imali virološku supresiju od najmanje tri mjeseca.
English: Cmin: ↓ 8% (↑ 14 to ↓ 25)
Croatian: Cmin: ↓ 8% (↑ 14 do ↓ 25)
English: Contains sodium, see leaflet for further information.
Croatian: POPIS POMOĆNIH TVARI Sadržava natrij, za dodatne informacije vidjeti uputu o lijeku.
English: Concomitant administration of atovaquone/proguanil with Atripla should be avoided.
Croatian: Istodobnu primjenu atovakvona/progvanila s Atriplom treba izbjegavati.
English: 1.2% (-2.3% to 6.7%)
Croatian: 1,2% (-2,3% do 6,7%)
English: Neither emtricitabine nor tenofovir inhibited in vitro drug metabolism mediated by any of the major human CYP isoforms involved in drug biotransformation.
Croatian: Ni emtricitabin niti tenofovir nisu inhibirali in vitro metabolizam lijekova koji se biotransformiraju pomoću bilo koje od glavnih CYP izoformi u ljudi.
English: Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week in combination with Atripla.
Croatian: U režimima gdje se rifabutin daje 2 ili 3 puta tjedno u kombinaciji s Atriplom treba razmotriti udvostručavanje
English: Decreased exposure of etonogestrel may be expected (CYP3A4 induction).
Croatian: Može se očekivati smanjenje izloženosti etonogestrelu (indukcija CYP3A4).
English: 8.9% (-7.7% to 25.6%)
Croatian: 8,9% (-7,7% do 25,6%)
English: Renal function should be closely monitored (see section 4.4).
Croatian: Nužno je pomno nadzirati funkciju bubrega (vidjeti odjeljak 4.4).
English: Prior NNRTI-based regimen (N=104)
Croatian: Prethodni režim temeljen na NNRTI lijekovima (N=104)
English: Atripla may affect your kidneys.
Croatian: Atripla može negativno utjecati na bubrege.
English: Because of the limited information available, a reliable method of barrier contraception must be used in addition to hormonal contraceptives (see section 4.6).
Croatian: Budući da su dostupne ograničene informacije, osim hormonskih kontraceptiva mora se koristiti i pouzdana metoda barijerne kontracepcije (vidjeti dio 4.6).
English: If a patient misses a dose of Atripla by more than 12 hours and it is almost time for the next dose, the patient should not take the missed dose and simply resume the usual dosing schedule.
Croatian: Ako bolesnik propusti uzeti dozu Atriple, a prošlo je više od 12 sati i uskoro je vrijeme za uzimanje sljedeće doze, bolesnik ne treba uzeti propuštenu dozu nego jednostavno nastaviti uzimati lijek prema svom uobičajenom rasporedu.
English: Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values.
Croatian: Istodobna primjena efavirenza s atorvastatinom, pravastatinom ili simvastatinom nije imalo učinak na vrijednosti efavirenza AUC ili Cmax.
English: - The other ingredients in the tablet are croscarmellose sodium, hyprolose, magnesium stearate, microcrystalline cellulose, sodium laurilsulfate.
Croatian: - Drugi sastojci tablete su umrežena karmelozanatrij, hiproloza, magnezijev stearat, mikrokristalična celuloza, natrijev laurilsulfat.
English: How to take Atripla
Croatian: Kako uzimati Atriplu
English: Driving and using machines Atripla may cause dizziness, impaired concentration and drowsiness.
Croatian: Atripla može uzrokovati omaglicu, manjak koncentracije i omamljenost.
English: Artemether:
Croatian: artemeter:
English: QT Prolonging Drugs: Atripla is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes, such as: antiarrhythmics of classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole), cisapride, flecainide, certain antimalarials and methadone (see section 4.3).
Croatian: Lijekovi koji produljuju QT interval: Lijek Atripla kontraindiciran je za istodobnu primjenu s lijekovima za koje je poznato da produljuju QTc interval i mogu dovesti do torsade de pointes, kao što su: antiaritmici skupina IA i III, neuroleptici i antidepresivi, određeni antibiotici uključujući neke lijekove iz sljedećih skupina: makrolidi, fluorokinoloni, antimikotici derivati imidazola i triazola, određeni nesedacijski antihistaminici (terfenadin, astemizol), cisaprid, flekainid, određeni antimalarici i metadon (vidjeti dio 4.3).
English: There were no clinically significant pharmacokinetic interactions when efavirenz was administered with azithromycin, cetirizine, fosamprenavir/ritonavir, lorazepam, nelfinavir, zidovudine, aluminium/magnesium hydroxide antacids, famotidine or fluconazole.
Croatian: Nema klinički značajnih farmakokinetičkih interakcija kada se efavirenz primjenjuje istodobno s azitromicinom, cetirizinom, fosampremavirom/ ritonavirom, lorazepamom, nelfinavirom, zidovudinom, antacidima koji sadržavaju hidroksid aluminija/magnezija, famotidinom ili flukonazolom.
English: Side effects to the liver: If you are also infected with hepatitis B virus, you may experience a worsening of hepatitis after discontinuation of treatment (see section 3).
Croatian: Nuspojave na jetri: ako ste inficirani i virusom hepatitisa B, nakon prekida liječenja može doći do pogoršanja hepatitisa (pogledajte dio 3).
English: (CYP3A induction - effect on boceprevir) *0-8 hours
Croatian: Cmax: ↔ 11% (indukcija CYP3A- učinak na boceprevir) *0-8 sati
English: The apparent clearance of tenofovir averaged approximately 307 ml/min.
Croatian: Prividni klirens tenofovira je u prosjeku iznosio oko 307 ml/min.
English: Your doctor may require you to take a pregnancy test to ensure you are not pregnant before starting treatment with Atripla.
Croatian: Vaš će liječnik prije početka liječenja Atriplom možda zatražiti da obavite test trudnoće kako biste bili sigurni da niste trudni.
English: No clinically significant pharmacokinetic interaction.
Croatian: Ne postoji klinički značajna farmakokinetička interakcija.
English: Following oral administration of a single 300 mg dose of tenofovir disoproxil to HIV-1 infected patients in the fasted state, maximum tenofovir concentrations were achieved within one hour and the Cmax and AUC (mean ± S.D.) (%CV) values were 296 ± 90 ng/ml (30%) and 2,287 ± 685 ng•h/ml (30%), respectively.
Croatian: Nakon peroralne primjene jedne doze 300 mg tenofovirdizoproksila natašte bolesnicima inficiranima virusom HIV-1, maksimalne koncentracije tenofovira postignute su unutar jednog sata, a vrijednosti Cmax i AUC (srednja vrijednost ± SD) (%CV) iznosile su 296 ± 90 ng/ml (30%), odnosno 2287 ± 685 ng•h/ml (30%).
English: When Atripla is taken with rifampicin in patients weighing 50 kg or greater, an additional 200 mg/day (800 mg total) of efavirenz may provide exposure similar to a daily efavirenz dose of 600 mg when taken without rifampicin.
Croatian: Kada se Atripla primjenjuje s rifampicinom u bolesnika tjelesne težine 50 kg ili više, s dodatnih 200 mg/dnevno (ukupno 800 mg) efavirenza može se postići izloženost efavirenzu slična onoj kod dnevne doze efavirenza od 600 mg kada se primjenjuje bez rifampicina.
English: The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action.
Croatian: Potencijal za križnu rezistenciju između efavirenza i NRTI lijekova nizak je zbog različitih mjesta vezivanja i različitih mehanizama djelovanja.
English: The safety and efficacy of Atripla in children under the age of 18 years have not been established (see section 5.2).
Croatian: Pedijatrijska populacija Sigurnost i djelotvornost Atriple u djece mlađe od 18 godina nisu ustanovljene (vidjeti dio 5.2).
English: Didanosine: Co-administration of Atripla and didanosine is not recommended (see section 4.4 and Table 1).
Croatian: Didanozin: ne preporučuje se istodobna primjena Atriple i didanozina (vidjeti dio 4.4 i Tablicu 1).
English: No dose adjustment is necessary for efavirenz.
Croatian: Nije potrebna prilagodba doze efavirenza.
English: Monitoring of renal function is recommended for patients receiving Atripla (see section 4.4).
Croatian: Preporučuje se praćenje funkcije bubrega u bolesnika koji primaju Atriplu (vidjeti dio 4.4).
English: If Atripla is co-administered with an NSAID, renal function should be monitored adequately.
Croatian: Ako se Atripla primjenjuje istodobno s NSAIL-om, potrebno je provjeravati funkciju bubrega na odgovarajući način.
English: How to store Atripla
Croatian: Kako čuvati Atriplu
English: Where discontinuation of therapy with one of the components of Atripla is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil are available.
Croatian: Kada je indiciran prekid terapije jednom od komponenti Atriple ili kada je nužno prilagođavanje doze, postoje odvojeni pripravci efavirenza, emtricitabina i tenofovirdizoproksila.
English: 0% (-2.4% to 4.2%)
Croatian: 0% (-2,4% do 4,2%)
English: - Medicines used to lower blood fats (also called statins): Atorvastatin, pravastatin,
Croatian: - Lijekovi koji se koriste za snižavanje razine masnoća u krvi (poznati i pod nazivom statini): atorvastatin, pravastatin, simvastatin.
English: Plasma levels of efavirenz can be reduced by concomitant use of St. John's wort due to induction of drug metabolising enzymes and/or transport proteins by St. John's wort.
Croatian: Razine efavirenza u plazmi mogu biti snižene u slučaju istodobnog uzimanja gospine trave jer ona inducira enzime koji metaboliziraju lijek i/ili transportne proteine.
English: Therefore co-administration of atazanavir/ritonavir and Atripla is not recommended (see Table 1).
Croatian: Iz tog se razloga ne preporučuje istodobna primjena atazanavira/ritonavira i Atriple (vidjeti Tablicu 1).
English: In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP-mediated interactions involving emtricitabine and tenofovir disoproxil with other medicinal products is low.
Croatian: In vitro i klinička ispitivanja farmakokinetičkih interakcija pokazala su da je potencijal za interakcije emtricitabina i tenofovirdizoproksila s drugim lijekovima, posredovane CYP sustavom, nizak.
English: HIV/HBV or HCV co-infected patients: Only a limited number of patients were co-infected with HBV (n = 13) or HCV (n = 26) in study GS-01-934.
Croatian: Bolesnici istodobno inficirani HIV/HBV-om ili HCV-om: U ispitivanju GS-01-934 samo je ograničeni broj bolesnika bio istodobno zaražen HBV-om (n=13) ili HCV-om (n=26).
English: Lopinavir concentrations: similar to lopinavir/ritonavir 400/100 mg twice daily without efavirenz.
Croatian: Koncentracije lopinavira: slične dozi lopinavira/ritonavira od 400/100 mg dva puta dnevno, bez efavirenza.
English: It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of Atripla on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section 5.1).
Croatian: Predviđa se da je izloženost tenofoviru (AUC) približno 30% manja nakon uzimanja Atriple na prazan želudac, u usporedbi s uzimanjem pojedinačne komponente tenofovirdizoproksila s hranom (vidjeti dio 5.1).
English: Patients with HIV and hepatitis B (HBV) or C virus (HCV) co-infection Patients with chronic hepatitis B or C and treated with CART are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Croatian: Bolesnici s istodobnom infekcijom virusom HIV-a i virusom hepatitisa B (HBV) ili C (HCV) Bolesnici s kroničnim hepatitisom B ili C liječeni CART-om izloženi su povećanom riziku od teških i potencijalno smrtonosnih jetrenih nuspojava.
English: In order to improve the tolerability to efavirenz with respect to undesirable effects on the nervous system, bedtime dosing is recommended (see section 4.8).
Croatian: Kako bi se povećala tolerancija na efavirenz s obzirom na nuspojave na živčanom sustavu, preporučuje se uzimanje prije spavanja (vidjeti dio 4.8).
English: Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine).
Croatian: Istodobna primjena s terfenadinom, astemizolom, cisapridom, midazolamom, triazolamom, pimozidom, bepridilom ili ergot alkaloidima (na primjer, ergotamin, dihidroergotamin, ergonovin i metilergonovin).
English: Use of Atripla should be avoided with concurrent or recent use of a nephrotoxic medicinal product.
Croatian: Treba izbjegavati primjenu Atriple istodobno s primjenom ili nakon nedavne primjene nefrotoksičnog lijeka.
English: Other medicines and Atripla You must not take Atripla with certain medicines.
Croatian: Atripla se ne smije uzimati zajedno s određenim lijekovima.
English: In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Croatian: U nekih bolesnika s uznapredovalom infekcijom virusom HIV-a (AIDS) i oportunističkim infekcijama u dosadašnjem tijeku bolesti mogu se ubrzo nakon početka liječenja infekcije virusom HIV-a pojaviti znakovi i simptomi upale od prethodnih infekcija.
English: Before starting treatment, your doctor may order blood tests to assess kidney function.
Croatian: Prije početka liječenja liječnik će možda zatražiti krvne pretrage da bi ocijenio rad bubrega.
English: In both studies, plasma progesterone levels for subjects receiving efavirenz and DMPA remained low consistent with suppression of ovulation.
Croatian: U oba istraživanja razine progesterona u plazmi u ispitanika koji su primali efavirenz i DMPA ostale su niske u skladu sa supresijom ovulacije.
English: In a 144-week controlled clinical study that compared tenofovir disoproxil with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve patients, small decreases in bone mineral density of the hip and spine were observed in both treatment groups.
Croatian: U kontroliranom kliničkom ispitivanju koje je trajalo 144 tjedna i u kojem je uspoređivan tenofovirdizoproksil sa stavudinom u kombinaciji s lamivudinom i efavirenzom u bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima, u obje je liječene skupine zapaženo malo smanjenje mineralne gustoće kosti kuka i kralježnice.
English: In addition, a K70E substitution in HIV-1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, lamivudine and tenofovir.
Croatian: Uz to, tenofovirom je izdvojena K70E supstitucija u HIV-1 RT što rezultira blagim smanjenjem osjetljivosti na abacavir, emtricitabin, lamivudin i tenofovir.
English: In vivo resistance (antiretroviral-naïve patients): In a 144-week open-label randomised clinical study (GS-01-934) in antiretroviral-naïve patients, where efavirenz, emtricitabine and tenofovir disoproxil were used as individual formulations (or as efavirenz and the fixed combination of emtricitabine and tenofovir disoproxil (Truvada) from week 96 to 144), genotyping was performed on plasma HIV-1 isolates from all patients with confirmed HIV RNA > 400 copies/ml at week 144 or early study drug discontinuation (see section on Clinical experience).
Croatian: In vivo rezistencija (bolesnici koji prije nisu bili liječeni antiretrovirusnim lijekovima): U otvorenom randomiziranom kliničkom ispitivanju u trajanju od 144 tjedna (GS-01-934) u kojem su bolesnicima koji prije nisu bili liječeni antiretrovirusnim lijekovima davani efavirenz, emtricitabin i tenofovirdizoproksil u pojedinačnim formulacijama (ili kao efavirenz i fiksna kombinacija doza emtricitabina i tenofovirdizoproksila (Truvada) 96. do 144. tjedna), izvršena je genotipizacija izolata virusa HIV-1 iz plazme svih bolesnika s potvrđenom koncentracijom HIV RNA > 400 kopija/ml u 144. tjednu ili u slučaju ranog prekida uzimanja ispitivanog lijeka (vidjeti dio Klinička iskustva).
English: Women of childbearing potential (see below and section 5.3)
Croatian: Žene reproduktivne dobi (pogledajte nastavak teksta i dio 5.3).
English: If the patient vomits within 1 hour of taking Atripla, another tablet should be taken.
Croatian: U slučaju da bolesnik povraća unutar 1 sata od uzimanja Atriple, treba uzeti još jednu tabletu.
English: Atripla has not been studied in patients over the age of 65.
Croatian: Atripla nije ispitivana u bolesnika starijih od 65 godina.